October 23, 2007 - Hologic Inc. and Cytyc Corp. recently announced the merging of the two companies, creating one of the largest companies in the world focused on advanced technology in women’s health.
Hologic will continue to trade on the NASDAQ Global Select Market under the symbol “HOLX” while Cytyc is now a wholly-owned subsidiary of Hologic and ceased trading on the NASDAQ as of the close of trading on Oct. 22.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostic and medical imaging systems dedicated to serving the healthcare needs of women and a developer of imaging technology for digital radiography and breast imaging. Hologic’s core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications.
Cytyc’s products cover a range of cancer and women’s health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer.
Under the terms of the merger agreement, Cytyc shareholders received 0.52 shares of Hologic common stock and $16.50 in cash for each share of Cytyc common stock held by them, with aggregate consideration paid to Cytyc shareholders totaling approximately $6.2 billion, payable in approximately 65.8 million shares of Hologic common stock and approximately $2.1 billion in cash.
For more information: www.hologic.com